CTX-120 is a gene-modified cell therapy commercialized by CRISPR Therapeutics, with a leading Phase I program in Relapsed Multiple Myeloma. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of CTX-120’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for CTX-120 is expected to reach an annual total of $48 mn by 2039 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
CTX-120 is under development for the treatment of multiple myeloma. The drug candidate consists of allogenic T cells engineered to express chimeric antigen receptors (CAR T-cells) targeting cells expressing B-cell maturation antigen (BCMA). It is developed based on CRISPR’s gene-editing technology. It is administered through intravenous route.
CRISPR Therapeutics Overview
CRISPR Therapeutics (CRISPR) is a gene editing company. It focuses on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a gene-editing technology that modifies, deletes, or corrects disease-causing abnormalities at its genetic sources. Its major development programs include ex vivo programs involving gene editing of hematopoietic cells; ex vivo programs in immuno-oncology; in vivo programs targeting the liver and additional in vivo programs targeting other organ systems including muscle and lung. It has research and development operations in Cambridge, Massachusetts, the US and business operations in London, the UK. CRISPR is headquartered in Zug, Switzerland.
The company reported revenues of (US Dollars) US$1.2 million for the fiscal year ended December 2022 (FY2022), a decrease of 99.9% over FY2021. The operating loss of the company was US$673.2 million in FY2022, compared to an operating profit of US$373.5 million in FY2021. The net loss of the company was US$650.2 million in FY2022, compared to a net profit of US$377.7 million in FY2021.
For a complete picture of CTX-120’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.